Clinical Trials Logo
  1. Home
  2. CRC
  3. NCT06455254

Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM

CRC Clinical Trial

Official title:
A Single-arm, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of Candonilimab（AK104） Combined With Regorafenib For the Third-line Treatment of MSS Colorectal Liver Metastasis

Clinical Trial Summary

This study is a single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of Candonilimab (AK104) combined with Regorafenib for the treatment of MSS colorectal liver metastasis. Candonilimab (AK104) is a humanized IgG1 bispecific antibody that targets PD-1 and CTLA-4.

Clinical Trial Description

This is a single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of Candonilimab (AK104) combined with Regorafenib for the treatment of MSS colorectal liver metastasis. The purpose of the study is to observe and evaluate the efficacy and safety of Cadonilimab in combination with Regorafenib in patients with CRLM who had failed the previous second-line standard regimen, and to explore biomarkers related to efficacy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06455254
Study type Interventional
Source Fudan University
Contact Jinhong Chen, M.D
Phone +8613801977742
Email jinhongch@hotmail.com
Status Not yet recruiting
Phase Phase 2
Start date June 2024
Completion date June 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Recruiting NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Active, not recruiting NCT01308086 - Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer Phase 3
Active, not recruiting NCT04585035 - Study to Evaluate D-1553 in Subjects With Solid Tumors Phase 1/Phase 2
Completed NCT03665285 - A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03336658 - Intratumoral Budding (ITB) in Preoperative Biopsies of Colon and Rectal Cancer
Recruiting NCT06445062 - Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors Phase 1/Phase 2
Terminated NCT03875313 - Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Phase 1/Phase 2
Recruiting NCT05382377 - NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors Early Phase 1
Active, not recruiting NCT05314309 - Prospective Clinical Validation of a Novel Multitarget FIT in CRC Screening
Recruiting NCT06259552 - A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors Phase 1
Completed NCT05976282 - Addressing Colorectal Cancer in South Florida Firefighters N/A
Recruiting NCT01593098 - A Prospective Study Into the Risk of Colorectal Neoplasms in Individuals With a Family History of Advanced Adenomas (Sibling AN Study)
Recruiting NCT03597581 - A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer Phase 1
Terminated NCT05368688 - Microbiome in Colorectal Cancer Onset and Progression
Completed NCT03965845 - A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT03601598 - A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC Phase 1/Phase 2
Completed NCT02161549 - Evaluation of the Motus Gl CleanUp System During Screening Colonoscopy N/A
Active, not recruiting NCT04868773 - Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy Phase 1